XANDRA
GARCÍA GONZÁLEZ
Profesora asociada de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Instituto de Investigación Sanitaria Gregorio Marañón (27)
2024
-
Treatment with Rasburicase in Hospitalized Patients with Cardiorenal Syndrome: Old Treatment, New Scenario
International Journal of Molecular Sciences, Vol. 25, Núm. 6
2023
-
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy
Frontiers in Oncology, Vol. 13
-
Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives
Journal of Personalized Medicine, Vol. 13, Núm. 3
2022
-
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
Biomedicine and Pharmacotherapy, Vol. 146
-
Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy
Clinical Microbiology and Infection, Vol. 28, Núm. 9, pp. 1287.e9-1287.e15
2021
-
Clinical evaluation of pulmonary hypertension using patient-reported outcomes: a cross-sectional study
BMC Pulmonary Medicine, Vol. 21, Núm. 1
-
Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach
Journal of Personalized Medicine, Vol. 11, Núm. 8
-
Pharmacogenetics to avoid adverse reactions in cardiology: Ready for implementation?
Journal of Personalized Medicine, Vol. 11, Núm. 11
-
Valganciclovir—Ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship
Antibiotics, Vol. 10, Núm. 1, pp. 1-18
2020
-
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Pharmacological Research, Vol. 152
-
Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease
Journal of pediatric gastroenterology and nutrition, Vol. 71, Núm. 4, pp. 508-515
-
Improving surgical antibiotic prophylaxis adherence and reducing hospital readmissions: A bundle of interventions including health information technologies
European Journal of Hospital Pharmacy, Vol. 27, Núm. 4, pp. 237-242
-
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine
Cancer Chemotherapy and Pharmacology, Vol. 86, Núm. 1, pp. 45-54
-
Topical Administration of Amphotericin B as an Effective Adjuvant Treatment for a Deep Fungal Infection of Diabetic Foot Injury
American journal of therapeutics, Vol. 27, Núm. 6, pp. e670-e671
2019
-
Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution
International Journal of Antimicrobial Agents, Vol. 53, Núm. 1, pp. 40-48
-
Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin
Journal of Oncology Pharmacy Practice, Vol. 25, Núm. 3, pp. 694-698
2018
-
Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan
Pharmacological Research, Vol. 136, pp. 133-139
-
Drug cost avoidance resulting from breast cancer clinical trials
European Journal of Clinical Pharmacy, Vol. 20, Núm. 1, pp. 6-10
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
-
Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
Cancer Management and Research, Vol. 10, pp. 4517-4522